Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Express Scripts
Moodys
McKesson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

King Pharms Llc Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for KING PHARMS LLC, and when can generic versions of KING PHARMS LLC drugs launch?

KING PHARMS LLC has twelve approved drugs.

There is one US patent protecting KING PHARMS LLC drugs.

There are forty-five patent family members on KING PHARMS LLC drugs in thirty-two countries and four supplementary protection certificates in three countries.

Summary for King Pharms Llc
International Patents:45
US Patents:1
Tradenames:12
Ingredients:11
NDAs:12

Drugs and US Patents for King Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms Llc CORZIDE bendroflumethiazide; nadolol TABLET;ORAL 018647-001 May 25, 1983 AB RX Yes No   Start Trial   Start Trial
King Pharms Llc TAPAZOLE methimazole TABLET;ORAL 040320-001 Mar 31, 2000 AB RX No No   Start Trial   Start Trial
King Pharms Llc AVINZA morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021260-002 Mar 20, 2002 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for King Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 4,587,258   Start Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 4,587,258   Start Trial
King Pharms Llc AVINZA morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021260-004 Mar 20, 2002 6,066,339   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for KING PHARMS LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 45 mg and 75 mg ➤ Subscribe 2009-07-30
➤ Subscribe Extended-release Capsules 30 mg, 60 mg, 90 mg and 120 mg ➤ Subscribe 2007-06-04

Supplementary Protection Certificates for King Pharms Llc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0265685 99C0001 Belgium   Start Trial PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
0265685 SPC/GB98/047 United Kingdom   Start Trial PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
0265685 C980030 Netherlands   Start Trial PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
Mallinckrodt
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.